|Publication number||US4213979 A|
|Application number||US 05/970,705|
|Publication date||Jul 22, 1980|
|Filing date||Dec 18, 1978|
|Priority date||Dec 18, 1978|
|Publication number||05970705, 970705, US 4213979 A, US 4213979A, US-A-4213979, US4213979 A, US4213979A|
|Inventors||Donald J. LeVine|
|Original Assignee||Plough, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (47), Classifications (20)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This invention relates to a stable, cosmetically elegant hydrocortisone hydroalcoholic solution useful for the relief of itching and inflammation associated with minor skin irritation when applied as a non-aerosol spray. It is relatively non-flammable and exhibits no microscopic crystallization. The preparation is primarily designed for the treatment of poison ivy and contact dermatitis, although it would also be useful for the treatment of minor burns, cuts, scratches, sunburn and other similar minor skin irritants.
Hydrocortisone, which is a naturally occuring steroid, is a white powder that is very slightly soluble in water but soluble in alcohol and glycol solvents. Its solubility at 25° C. in water, ethanol and propylene glycol is 0.28, 15.0 and 12.7 mg/ml, respectively. It is also known as cortisol.
Hydrocortisone has been marketed in the United States since 1952 as a prescription drug and is recognized as one of the most potent and effective agents for the treatment of many common dermatoses. It has been commonly used for many years in various topical prescription preparations as an antipruritic and anti-inflammatory agent in the 0.5-5.0 percent dosage range. In recent years it has been used topically in a dosage range of 0.1-0.25 percent. It has recently been recommended by the OTC Topical Analgestic Panel of the FDA as a safe and effective topical analgesic product when applied at 0.25-0.50 percent to affected areas of the skin 3 to 4 times daily.
Topical hydrocortisone compositions have traditionally been sold in the form of ointments, lotions and creams. In U.S. Pat. No. 3,456,052 an aerosol ointment form was disclosed. Hydroalcoholic lotion solutions are also known but are generally found to be unstable, particularly at low temperature, with small amounts of hydrocortisone crystallizing out. This problem is not a great concern in these preparations since a small degree of crystallization will usually not seriously affect the use of a lotion which is rubbed on the skin, although if the crystallization is severe enough it could irritate inflamed, sensitive skin. In a spray device this problem is serious since even microscopic crystals can block the outlet orifice of the container and render the device inoperable.
The spray is a particularly desirable form since it is convenient and presents no danger of contamination to the product. A spray would also provide a generally cooling effect on the inflamed skin and cause less irritation to sensitive skin than would be produced by the rubbing on of a lotion or the like. However, the aerosols containing fluorocarbon propellants are undesirable for environmental reasons and the hydrocarbon propellants are highly flammable.
I have now surprisingly discovered a stable, relatively non-flammable, cosmetically elegant, sprayable topical hydrocortisone composition which is particularly suited for use in a non-aerosol spray assembly.
The key ingredient in the formulation which stabilizes the hydrocortisone is polyoxypropylene-(12)-polyoxyethylene-(50)-lanolin. This compound, whose CTFA recognized name is PPG-12-PEG-50-Lanolin, is the polyoxypropylene, polyoxyethylene derivative of lanolin that conforms generally to the formula ##STR1## where R represents the lanolin radicals, x has an average value of 12 and y has an average value of 50. It is sold commercially under the tradename LANEXOL AWS by Croda, Inc. Its principal use has been in hair preparations, soaps, creams, antiperspirants and lotions where the properties of lanolin would be advantageous.
The preferred formulation particularly suited for use in a pump spray device is an aqueous solution containing 0.2-1.0 percent of hydrocortisone; 0.2-1.0 percent of polyoxypropylene-(12)-polyoxyethylene-(50)-lanolin; 15-35 percent of a cosmetically acceptable, water-miscible alcohol solvent in which the hydrocortisone is soluble; 10-35 percent of a cosmetically acceptable glycol solvent which is a liquid at 25° and in which the hydrocortisone is soluble; and at least 50 percent water. The resulting formulation is physically stable at low temperatures, chemically stable at higher temperatures, does not excessively dry the skin, exhibits a good spray pattern, and does not exhibit the high flammability characteristically associated with high concentrations of flammable solvents.
The most preferred pump spray formulations contain 0.25 to 0.5 percent of hydrocortisone and 0.3 to 0.7 percent of the polyoxypropylene-(12)-polyoxyethylene-(50)-lanolin. This formula would also preferably contain 15-25 percent of ethanol; 10-25 percent of propylene glycol, wherein the maximum concentration of the alcohol and glycol solvents is 45 percent; and 55-60 percent of water. Another suitable water-miscible alcohol solvent is isopropyl alcohol. Other suitable water-miscible glycol solvents are polypropylene glycol and peroxide-free polyethylene glycol having a molecular weight of 200-600.
The formulation can be utilized in conjunction with any non-aerosol spray assembly. Many such spray assemblies are widely known and used, such as the squeeze spray assembly shown in U.S. Pat. Nos. 3,361,304 and 3,474,936 (which are herein incorporated by reference), or the pump spray system shown in U.S. Pat. Nos. 4,010,874 and 4,022,354 (which are also herein incorporated by reference). The spray assembly will generally comprise a reservoir for holding the sprayable composition; a means for mixing the composition with air; and a means to dispense the air/liquid mixture as a spray. This is usually accomplished by creating a pressure differential between the atmosphere and the inside of the container, e.g. a pumper or squeezing a resilient container wall.
I have found that in our alcohol-glycol system the hydrocortisone is particularly stable at a pH of 4.0-5.0. In order to achieve this preferred pH range, it is generally necessary to downwardly adjust the pH of the formulation with a suitable dilute acid solution, e.g. 20% w/w phosphoric acid solution. It is generally known that hydrocortisone is more stable in an acid environment but it was not generally known that a narrow pH range of 4.0-5.0 was particularly suited in an alcohol-glycol aqueous system.
Various optional ingredients may be included in the formulation such as perfumes; preservatives, e.g. parabens; antiseptics, e.g. triclosan, phenol; humectants; emollients; antioxidants; chelating agents, e.g. disodium EDTA; dyes; foaming agents; as well as any other class of material whose presence may be cosmetically or otherwise desirable.
The following non-limiting Examples are presented to illustrate the invention. The terminology is in conformance to the CTFA Cosmetics Ingredient Dictionary, published by the Cosmetic, Toiletries and Frangrance Assoc., Wash., D.C., 2nd Edition, 1977. The percentages used throughout the specification are weight percents unless indicated otherwise.
A topical anti-inflammatory solution is prepared according to the following preferred formulation:
______________________________________Part AHydrocortisone 0.5Ethanol 20.0Propylene Glycol 20.0Part BPPG-12-PEG-50-Lanolin 0.5Disodium EDTA 0.1Water 58.9 100.0______________________________________
The ingredients of Part A are agitated at room temperature until all solids dissolve. The ingredients of Part B are agitated at room temperature until all solids dissolve. The mixture of Part A is then blended with the mixture of Part B. The pH of the resulting formulation is downwardly adjusted from 6.4 to 4.5 with a dilute phosphoric acid solution.
______________________________________Part AHydrocortisone 0.5Alcohol 30.0Propylene Glycol 10.0Part BPPG-12-PEG-50-Lanolin 0.5Disodium EDTA 0.1Water 58.9 100.0______________________________________
The above formula is prepared in a similar manner to Example 1. The pH of the resulting formulation is downwardly adjusted from 6.5 to 4.5 with a dilute phosphoric acid solution.
______________________________________Part AHydrocortisone 0.5Alcohol 15.0Propylene Glycol 25.0Part BPPG-12-PEG-50-Lanolin 0.5Methyl Paraben 0.2Water 58.8 100.0______________________________________
The above formula is prepared in a manner similar to Example 1. The pH of the resulting formulation is downwardly adjusted from 6.2 to 4.5 with a dilute hydrochloric acid solution.
______________________________________Part AHydrocortisone 0.5Alcohol 15.0Propylene Glycol 25.0Part BPPG-12-PEG-50-Lanolin 1.0Methyl Paraben 0.2Water 58.3 100.0______________________________________
The above formula is prepared in a manner similar to Example 1. The pH of the resulting formulation is downwardly adjusted from 6.2 to 4.5 with a dilute citric acid solution.
Formulas prepared according to the above Examples provide a soothing and cooling effect when sprayed on inflamed skin. The formulations are physically stable at low temperatures, chemically stable at high temperatures, and do not block the orifice when used in a non-aerosol spray device. They provide a good spray pattern when sprayed from a pump dispenser. They do not unduly dry the skin and are relatively non-flammable.
Numerous other variants of the above formulations will be apparent to one skilled in the art and within the spirit of the invention.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4083974 *||Mar 7, 1977||Apr 11, 1978||The Upjohn Company||Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5272139 *||May 29, 1991||Dec 21, 1993||Cary George R Jr||Amelioration or elimination of postoperative pain|
|US5728690 *||Mar 18, 1996||Mar 17, 1998||American Home Products Corporation||Clear non-alcoholic hydrocortisone solutions|
|US6723714||Jul 6, 1999||Apr 20, 2004||Blansett Pharmacal Co., Inc.||Aqueous solvent for corticosteroids|
|US6777401||Oct 24, 2002||Aug 17, 2004||Blansett Pharmacal, Co., Inc.||Aqueous solvent for corticosteroids|
|US7575739||Apr 28, 2004||Aug 18, 2009||Foamix Ltd.||Foamable iodine composition|
|US7601731 *||Jun 7, 2004||Oct 13, 2009||Board Of Regents, The University Of Texas System||Antimicrobial flush solutions|
|US7645803||May 9, 2006||Jan 12, 2010||Foamix Ltd.||Saccharide foamable compositions|
|US7704518||May 9, 2006||Apr 27, 2010||Foamix, Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US7820145||Oct 26, 2010||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8114385||Dec 26, 2006||Feb 14, 2012||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8119106||Jul 8, 2009||Feb 21, 2012||Foamix Ltd||Foamable iodine compositions|
|US8119109||Mar 13, 2007||Feb 21, 2012||Foamix Ltd.||Foamable compositions, kits and methods for hyperhidrosis|
|US8119150||Jul 6, 2006||Feb 21, 2012||Foamix Ltd.||Non-flammable insecticide composition and uses thereof|
|US8343945||Jun 7, 2010||Jan 1, 2013||Foamix Ltd.||Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof|
|US8362091||Jan 29, 2013||Foamix Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US8435498||May 7, 2013||Foamix Ltd.||Penetrating pharmaceutical foam|
|US8486374||Jan 14, 2008||Jul 16, 2013||Foamix Ltd.||Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses|
|US8486375||Feb 20, 2012||Jul 16, 2013||Foamix Ltd.||Foamable compositions|
|US8486376||Apr 6, 2005||Jul 16, 2013||Foamix Ltd.||Moisturizing foam containing lanolin|
|US8512718||Feb 12, 2010||Aug 20, 2013||Foamix Ltd.||Pharmaceutical composition for topical application|
|US8518376||Oct 6, 2009||Aug 27, 2013||Foamix Ltd.||Oil-based foamable carriers and formulations|
|US8518378||Sep 14, 2010||Aug 27, 2013||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8618081||May 4, 2011||Dec 31, 2013||Foamix Ltd.||Compositions, gels and foams with rheology modulators and uses thereof|
|US8636982||Aug 7, 2008||Jan 28, 2014||Foamix Ltd.||Wax foamable vehicle and pharmaceutical compositions thereof|
|US8703105||Mar 11, 2013||Apr 22, 2014||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8709342||Sep 17, 2012||Apr 29, 2014||Board Of Regents, The University Of Texas System||Antimicrobial flush solutions|
|US8709385||Jul 14, 2010||Apr 29, 2014||Foamix Ltd.||Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses|
|US8722021||Mar 6, 2013||May 13, 2014||Foamix Ltd.||Foamable carriers|
|US8741265||Mar 4, 2013||Jun 3, 2014||Foamix Ltd.||Penetrating pharmaceutical foam|
|US8758782 *||Mar 10, 2010||Jun 24, 2014||Galderma Research & Development||Excipient preservatives and pharmaceutical compositions comprised thereof|
|US8795635||May 12, 2010||Aug 5, 2014||Foamix Ltd.||Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses|
|US8795693||Nov 29, 2007||Aug 5, 2014||Foamix Ltd.||Compositions with modulating agents|
|US8840869||Apr 28, 2005||Sep 23, 2014||Foamix Ltd.||Body cavity foams|
|US8865139||Jul 9, 2014||Oct 21, 2014||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US8871184||Oct 1, 2010||Oct 28, 2014||Foamix Ltd.||Topical tetracycline compositions|
|US8900553||Jun 7, 2010||Dec 2, 2014||Foamix Pharmaceuticals Ltd.||Oil and liquid silicone foamable carriers and formulations|
|US8900554||Feb 20, 2012||Dec 2, 2014||Foamix Pharmaceuticals Ltd.||Foamable composition and uses thereof|
|US8945516||Oct 1, 2010||Feb 3, 2015||Foamix Pharmaceuticals Ltd.||Surfactant-free water-free foamable compositions, breakable foams and gels and their uses|
|US8992896||Aug 27, 2014||Mar 31, 2015||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US9050253||Apr 7, 2014||Jun 9, 2015||Foamix Pharmaceuticals Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US9072667||Jan 27, 2012||Jul 7, 2015||Foamix Pharmaceuticals Ltd.||Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9078441||Apr 15, 2014||Jul 14, 2015||Board Of Regents, The University Of Texas System||Antimicrobial flush solutions|
|US9101662||Oct 3, 2013||Aug 11, 2015||Foamix Pharmaceuticals Ltd.||Compositions with modulating agents|
|US20040180870 *||Mar 25, 2004||Sep 16, 2004||Calvin Hanna||Aqueous solvent for corticosteroids|
|US20050013836 *||Jun 7, 2004||Jan 20, 2005||Board Of Regents, The University Of Texas System||Antimicrobial flush solutions|
|US20100222333 *||Mar 10, 2010||Sep 2, 2010||Galderma Research & Development||Excipient preservatives and pharmaceutical compositions comprised thereof|
|EP0752247A1 *||Jul 3, 1996||Jan 8, 1997||Surtech International Ltd.||Compositionss containing corticosteroids and chlorinated phenols for the treatment of atopic eczema|
|International Classification||A61K8/63, A61Q17/00, A61K9/00, A61K47/44, A61Q19/00, A61K8/92|
|Cooperative Classification||A61K8/925, A61Q17/00, A61K9/0014, A61K47/44, A61K2800/75, A61K8/63, A61Q19/00|
|European Classification||A61Q17/00, A61Q19/00, A61K9/00M3, A61K8/63, A61K47/44, A61K8/92F|